

Synthesis and Structure of *N*-Methyl-1-[(4-bromo-3,5-dimethyl-1*H*-pyrazol-1-yl)phenyl]fullerene- C_{60} -[1,9-*c*]pyrrolidine

S. D. Fazylov^a, O. A. Nurkenov^a, A. E. Arinova^a, T. M. Seilkhanov^b, A. R. Tuktarov^c,
A. A. Khuzin^c, R. E. Bakirova^a, and L. E. Muravleva^a

^a Institute of Organic Synthesis and Coal Chemistry of the Republic of Kazakhstan,
ul. Alikhanova 1, Karaganda, 100008 Kazakhstan
e-mail: iosu8990@mail.ru

^b Ualikhanov Kokshetau State University, Kokshetau, Kazakhstan

^c Institute of Petroleum Chemistry and Catalysis, Russian Academy of Sciences, Ufa, Russia

Received January 12, 2015

Abstract—Three-component condensation of fullerene C_{60} with sarcosine and 4-(4-bromo-3,5-dimethyl-1*H*-pyrazol-1-yl)benzaldehyde under the conditions of the Prato reaction has afforded new fulleropyrrolidine; the product structure has been confirmed by IR and NMR spectroscopy as well as mass spectrometry.

Keywords: fullerene functionalization, fullerene C_{60} , fulleropyrrolidine, the Prato reaction

DOI: 10.1134/S1070363215050072

Fullerenes and their derivatives possess a range of valuable physical, photo- and electrochemical properties leading to a variety of potential medical applications. Fullerenes as such are extremely hydrophobic and therefore are hardly suitable for administration to a living organism. However, the recently developed methods of fullerenes chemical modifications using water-soluble and lipophilic adducts have allowed preparation of the derivatives revealing various biological effects [1]: absorption of free radicals and protection from oxidative stress [2], transfer of HIV proteases [3], and generation of singlet oxygen causing damage of DNA of the transformed (tumor) cells [4]. Certain organic derivatives of fullerenes are capable of penetration through lipid membranes, overcoming hematoencephalic barrier, and modulation of ions transport [5]. Lipophilic and membranotropic properties of fullerene C_{60} are essentially important for development of drugs efficient against pathogenic agents.

Functionalizing of fullerene sphere based on the Prato reaction [6] has recently become a leading method in targeted synthesis of new materials and bioactive compounds. Accessibility of various aldehydes has allowed preparation of a series of dimeric and trimeric donor–acceptor dyes and


investigation of their photophysical and biological properties [5, 7]. *N*-Methyl-1-(4-aminophenyl)fullero- C_{60} -[1,9-*c*]pyrrolidines based on novel 4-*N*-aminobenzaldehydes (4-morpholyl- and 4-piperidiylbenzaldehyde) have been described earlier in [8].

Herein we describe preparation and structure elucidation of another fulleropyrrolidine, *N*-methyl-1-[(4-bromo-3,5-dimethyl-1*H*-pyrazol-1-yl)phenyl]fullero- C_{60} -[1,9-*c*]pyrrolidine, starting from 4-(4-bromo-3,5-dimethyl-1*H*-pyrazol-1-yl)benzaldehyde **I** [9].

Three-component condensation of fullerene C_{60} , *N*-methylglycine (sarcosine), and 4-(4-bromo-3,5-dimethyl-1*H*-pyrazol-1-yl)benzaldehyde was performed under the conditions of Prato reaction in toluene upon heating during 4–5 h. After the reaction was complete, the unreacted starting compound and the reaction product **II** were separated by means of column chromatography on SiO_2 eluting sequentially with toluene and pyridine. The unreacted fullerene was eluted first; yield of the target fulleropyrrolidine **II** was of 88% (Scheme 1).


Mechanism of fulleropyrrolidine **II** formation likely included 1,3-dipolar addition to fullerene C_{60} through the intermediate formation of active azomethynilides [6]. Condensation of the aromatic aldehyde with

Scheme 1.



sarcosine via nucleophilic addition of the amino group of sarcosine at the carbonyl group of aldehyde **I** was the first reaction stage. The formed adduct further eliminated a water molecule and then underwent decarboxylation to form azo-ylide, the latter acting as a

nucleophile attacking the fullerene core at the 6–6 double bond to close the pyrrolidine ring. Structure of the prepared compound **II** was elucidated using data of IR, ^1H and ^{13}C NMR (COSY, HSQC, and HMBC experiments) as well as mass spectrometry.



Scheme of the correlations in HSQC (a), COSY (b), and HMBC (c) spectra of compound **II**.

IR spectrum of compound **II** contained absorption bands of pyridine ring C–N bonds, the fullerene fragment, and C–H and N–H bonds.

^1H NMR spectrum of compound **II** contained singlet signals of the methyl group protons at 2.30–2.86 ppm. The signals at 4.32–4.34 and 5.03–5.05 ppm were assigned to protons of the tertiary (C^2) and secondary (C^5) atoms of the saturated heterocycle, respectively. Equivalent protons of the aromatic fragment resonated in weak field at 7.51–7.67 and 7.96–8.02 ppm.

^{13}C NMR spectrum of compound **II** contained the methyl group signals at 12.07 (C^{20}), 12.43 (C^{18}), and 40.06 (C^6) ppm. The methylene and methine carbon atoms of the saturated aza-heterocycle resonated at 69.88 and 68.92 ppm, respectively. Signals of the aromatic fragment appeared in weak field at 123.91–124.50 and 130.19–130.72 ppm. The quaternary C^3 and C^4 atoms resonated as singlet signals at 97.07 ppm.

Six correlations were observed in the HSQC ^1H – ^{13}C spectrum, indicating the spin-spin coupling between the following pairs of atoms: H^{18} and C^{18} , H^{20} and C^{20} , H^6 and C^6 , H^2 and C^2 , H^5 and C^5 , H^9 and C^9 , H^{11} and C^{11} , H^8 and C^8 , H^{12} and C^{12} (see figure).

Molecular ion peak with m/z 1027.021 was detected in mass spectrum of compound **II**.

The prepared *N*-methyl-1-[(4-bromo-3,5-dimethyl-1*H*-pyrazol-1-yl)phenyl]fullero- C_{60} -[1,9-*c*]pyrrolidine **II** is of interest not as a biologically active compound as well as for organic photovoltaics applications [6] due to the presence of fullerene sphere, pyrrolidine ring, and pyrazole fragment in the structure.

EXPERIMENTAL

IR spectrum was recorded with an AVATAR-320 Nicolet Fourier spectrometer (KBr pellets). ^1H and ^{13}C NMR spectra were registered using a Bruker Avance-400 (500 MHz) spectrometer (solution in CDCl_3 – CS_2 1 : 5 with TMS as internal reference). Mass spectrum was obtained with a MALDI TOF/TOF Autoflex-III Bruker instrument. TLC analysis was performed on a Sorbfil plates developed with iodine vapor.

Fullerene C_{60} (99.5% purity) was purchased from NeoTekProduct (Saint Petersburg).

***N*-Methyl-1-[(4-bromo-3,5-dimethyl-1*H*-pyrazol-1-yl)phenyl]fullero- C_{60} -[1,9-*c*]pyrrolidine (II).** A mixture of a solution of 40 mg (0.0555 mmol) of C_{60} in

40 mL of toluene, 80 mg (0.0275 mmol) of 4-(4-bromo-3,5-dimethyl-1*H*-pyrazol-1-yl)benzaldehyde, and 9.8 mg (0.1112 mmol) of *N*-methylglycine was heated under reflux during 4 h. After the solvent removal, the residue was purified via column chromatography on silica gel eluting first with toluene to remove unreacted C_{60} and then with pyridine to isolate the fulleropyrrolidine **II**. Yield 24.6 mg (88%). ^1H NMR spectrum, δ , ppm: 2.33 s (3H, CH_3), 2.30 s (3H, CH_3), 2.86 s (3H, CH_3), 7.51 d (1H, $\text{CH}_{\text{arom}}^9$, J_{HH} 6.8 Hz), 7.67 d (1H, $\text{CH}_{\text{arom}}^{11}$, J_{HH} 6.4 Hz), 7.95 d (1H, $\text{CH}_{\text{arom}}^8$, J_{HH} 6.8 Hz), 8.01 d (1H, $\text{CH}_{\text{arom}}^{12}$, J_{HH} 6.4 Hz). ^{13}C NMR spectrum, δ_{C} , ppm: 135.53–156.09 (58C, fullerene), 154.71 (C^{12}), 131.43 (C^{10}), 129.96 (C^8), 127.77 (C^9), 115.18 (C^{11}), 113.34 (C^7), 83.03 (C^{16}), 69.77 (C^{15}), 68.66 (C^{14}), 66.22 (C^5), 66.29 (C^4), 48.79 (C^2), 47.32 (C^4), 39.79 (C^{18}), 29.83 (C^{13}). Mass spectrum, m/z (I_{rel} , %): 1027.021 [M] $^+$ (calculated for $\text{C}_{74}\text{H}_{22}\text{BrN}_3$: 1026.095).

REFERENCES

1. Bosi, S., Da Ros, T., Spalluto, G., and Prato, M., *Eur. J. Med. Chem.*, 2003, vol. 38, no. 11–12, p. 913. DOI: 10.1016/j.ejmech.2003.09.005.
2. Hirsch, A., Li, Q., and Wudl, F., *Angew. Chem. Int. Ed.*, 1991, vol. 30, p. 1309. DOI: 10.1002/anie.199113091.
3. Friedman, S.H., Decamp, D.L., Sijbesma, R.P., Strodanov, G., Wudl, F., and Kenyon, G.L., *J. Am. Chem. Soc.*, 1993, vol. 115, no. 15, p. 6506. DOI: 10.1021/ja00068a005.
4. Wang, J., Kawde, A.N., and Musameh, M., *Analyst*, 2003, vol. 128, p. 912. DOI: 10.1039/b303282e.
5. Bosi, S., Da Ros, T., Spalluto, G., Balzarini, J., and Prato, M., *Bioorg. Med. Chem. Lett.*, 2003, vol. 13, p. 4437. DOI: 10.1016/j.bmcl.2003.09.016.
6. *Fullerenes* (Fullerenes), Ed. by Sidorov, L.N., Yurovskaya, M.A., Borshchevskii, A.Ya., Trushkov, I.V., and Ioffe, I.N., Eds., Moscow: Ekzamen, 2005.
7. Zhang, J., Porfyrakis, K., Morton, J.J.L., Sambrook, M.R., Harmer, J., Xiao, L., Ardavan, A., and Briggs, G.A.D., *J. Phys. Chem.*, 2008, vol. 112, no. 8, p. 2802. DOI: 10.1021/jp711861z.
8. Fazylov, S.D., Nurkenov, O.A., Arinova, A.E., Tuktarov, A.R., Khuzin, A.A., and Turdybekov, K.M., *Russ. J. Gen. Chem.*, 2014, vol. 84, no. 10, p. 2058. DOI: 10.1134/S1070363214100375.
9. Fazylov, S.D., Nurkenov, O.A., Arinova, A.E., Satpaeva, Zh.B., Seilkhanov, T.M., Zkakupova, A.N., and Tolepbek, I.S., *Russ. J. Gen. Chem.*, 2014, vol. 84, no. 12, p. 2475. DOI: 10.1134/S1070363214120263.